Medipal Holdings Corp

Medipal Holdings Corp maintains a strong liquidity position, with cash and equivalents amounting to ¥261.4 billion, representing 14.3% of total assets. The company's liquidity FPT score of 0.91 indicates a healthy cash position relative to its liabilities, supported by a current ratio of 1.27 and free cash flow of ¥44.98 billion. The low debt-to-equity ratio of 0.01 further reinforces its conservative capital structure. Profitability metrics show a return on equity of 6.5% and return on assets of 2.21%, which are below the industry median for pharmaceutical companies. The operating margin of 15.1% (¥55.49 billion operating income on ¥367.13 billion revenue) is in line with the sector average, but the net margin of 11.0% (¥40.28 billion net income) suggests efficient cost management. The company's gross margin of 6.95% (¥25.58 billion gross profit) indicates moderate pricing power in its core operations. Geographically, Medipal Holdings Corp's revenue is concentrated in Japan, with no disclosed international segments. The company operates a single business segment focused on pharmaceuticals and medical research, with no material diversification across product lines or geographic regions. This concentration increases exposure to domestic regulatory and economic shifts. Revenue growth has been stable, with a current fiscal year outlook projecting a 2.5% increase to ¥376.6 billion. The next fiscal year is expected to see a 3.0% growth to ¥387.9 billion, driven by new product launches and expanded market share in domestic healthcare services. Over the past three years, revenue has grown at a compound annual rate of 4.2%, supported by consistent operating cash flow generation. Risk factors include low liquidity risk and no immediate dilution pressure, with a dilution potential score of 0.15. The company has no material short-term debt obligations, and its shares outstanding have remained stable at 204.7 million. No recent equity issuance or ATM programs have been disclosed, and the risk assessment indicates no filing-based flags for dilution. Recent events include a 10-K filing disclosing no material changes in business operations or regulatory compliance. Analysts have assigned a mean price target of ¥2,806, with a median of ¥2,700, and a mean recommendation of 3.2 (Hold). No strong buy or buy ratings have been issued, reflecting cautious sentiment among analysts.